Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Europe Down Syndrome Market – Industry Trends and Forecast to 2028

Pharmaceutical | Published Report | Mar 2021 | Europe | 350 Pages | No of Tables: 238 | No of Figures: 18

Report Description

Europe Down Syndrome Market, By Disease Type (Trisomy 21, Translocation Down Syndrome, Mosaic Down Syndrome), Treatment (Diagnosis, Therapy), End User (Hospital, Clinics, Homecare Setting, Therapy Centers, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania and Rest of Europe) Industry Trends and Forecast to 2028

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: Europe Down Syndrome Market

Down syndrome market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 13.78% in the forecast period of 2021 to 2028 and is expected to reach USD 725.12 million by 2028. Rising awareness about the disease and increasing prevalence of Down syndrome are the major drivers which propelled the demand of the market in the forecast period.

Technological advancements and increasing government support are the major drivers which have propelled the demand of the Down syndrome market in the forecast period.

Down syndrome is a genetic disease happens due to abnormal cell division. The abnormal cell division causes a gain of extra full or partial copy of chromosome number 21. The presence of extra genetic material causes the physical and developmental changes among the people leading to Down syndrome. The most common genetic abnormality associated with Down syndrome includes mental disabilities majorly learning disabilities in the children.

Awareness has allowed these people to opt for novel diagnostic approaches along with advanced therapies so as to lay a healthy lifestyle. This thus signifies that rising awareness about the disease is acting as driver for the Down syndrome market growth. The complications signify that unavailability of any specific treatment acts as restrain for the Down syndrome market growth. The market players operating in Down syndrome market are adopting several strategic initiatives expected to fuel up their business in various dimensions acting as an opportunity for the Down syndrome market growth. The long approval time associated with product launch acts as challenge for the Down syndrome market growth.

The Down syndrome market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the Down syndrome market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

Down Syndrome Market Scope and Market Size

The Down syndrome market is segmented on the basis of disease type, treatment, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the Down syndrome market is segmented into trisomy 21, translocation Down syndrome and mosaic Down syndrome. In 2021, trisomy 21 segment is dominating the market as more than 95 percent of cases of Down syndrome are trisomy 21.
  • On the basis of treatment, the Down syndrome market is segmented into diagnosis and therapy. In 2021, diagnosis segment is dominating the market as most of the parents undertake prenatal tests to understand the condition of the fetus.
  • On the basis of end user, the Down syndrome market is segmented into hospital, clinics, homecare setting, therapy centers and others. In 2021, hospital segment is dominating the market because they are the primary establishments for prenatal testing.
  • On the basis of distribution channel, the Down syndrome market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is dominating in the market as it is the primary mode of purchase of diagnostic products by hospitals and clinics.

Down Syndrome Market Country Level Analysis

Down syndrome market is analyzed and market size information is provided by the country, disease type, treatment, end user and distribution channel as referenced above.

The countries covered in the Down syndrome market report are the Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, and Rest of Europe.

Europe is expected to grow with the highest CAGR in the forecast period as the diagnosis of Down syndrome is a routine test in most countries. Germany is expected to dominate in the market in the Europe market. Germany is one of the leading countries which have huge market potential in Europe and higher demand for Down syndrome diagnosis.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Government Support and Increasing Research and Development are Boosting the Market Growth of Down syndrome

Down syndrome market also provides you with detailed market analysis for every country growth in Down syndrome industry with Down syndrome drugs sales, impact of advancement in the Down syndrome technology and changes in regulatory scenarios with their support for the Down syndrome market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Down syndrome Market Share Analysis

Down syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Down syndrome market.

The major companies which are dealing in the Down syndrome are F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Abbott, Natera, Inc, AtilaBiosystems, Physio.co.uk, Novus Biologicals (a subsidiary of Bio-Techne), Down Syndrome Cork, a branch of Down Syndrome Ireland, Demeditec Diagnostics GmbH, Symbol, ASDclinic.co.uk among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the Down syndrome market.

For instance,

  • In April 2017, Illumina, Inc. launched VeriSeq NIPT solution in Europe. The product launched is a CE-IVD marked next-generation sequencing technology-based approach used for screening of chromosomal abnormalities and proved efficacious for providing accurate information about chromosomal status within 10 weeks of gestation. This product launch boosted the company’s product portfolio and allowed it to penetrate its root in worldwide Down syndrome market.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the Down syndrome market which also provides the benefit for organization to improve their offering for Down syndrome.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE DOWN SYNDROME MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT OF DOWN SYNDROME LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 EUROPE DOWN SYNDROME MARKET: PIPELINE ANALYSIS

4.1 PIPELINE PRODUCTS IMPACT ANALYSIS

4.2 NNI-351

4.3 ASPARAGINASE

4.4 ANVS-401

4.5 QUILLIVANT XR

4.6 TOFACITINIB

4.7 MEMANTINE HYDROCHLORIDE

4.8 NICOTINE

4.9 AEF0217

4.1 ACI-24

5 EUROPE DOWN SYNDROME MARKET: LAWS AND REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF DOWN SYNDROME

6.1.2 RISING DEMAND OF EFFECTIVE THERAPIES

6.1.3 RISING AWARENESS ABOUT THE DISEASE

6.1.4 TECHNOLOGICAL ADVANCEMENTS

6.1.5 INCREASING GOVERNMENT SUPPORT

6.2 RESTRAINTS

6.2.1 UNAVAILABILITY OF ANY SPECIFIC TREATMENT

6.2.2 SIDE EFFECTS ASSOCIATED WITH DOWN SYNDROME TREATMENT THERAPIES

6.2.3 HIGH COST OF DIAGNOSIS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.2 INCREASING RESEARCH AND DEVELOPMENT

6.3.3 PRESENCE OF PIPELINE THERAPIES

6.3.4 PRESENCE OF REIMBURSEMENT

6.4 CHALLENGES

6.4.1 LACK OF SKILLED PROFFESSIONALS

6.4.2 LONG PROCESS FOR PRODUCT LAUNCH

6.4.3 TRANSFER OF COVID-19 INFECTIONS BY DIAGNOSTIC METHODS

7 IMPACT OF COVID-19 ON EUROPE DOWN SYNDROME MARKET

7.1 PRICE IMPACT

7.2 IMPACT ON SUPPLY CHAIN

7.3 IMPACT ON DEMAND

7.4 STRATEGIC DECISIONS FOR MANUFACTURERS

7.5 CONCLUSION

8 EUROPE DOWN SYNDROME MARKET, BY DISEASE TYPE

8.1 OVERVIEW

8.2 TRISOMY 21

8.3 TRANSLOCATION DOWN SYNDROME

8.4 MOSAIC DOWN SYNDROME

9 EUROPE DOWN SYNDROME MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 DIAGNOSIS

9.2.1 SCREENING TESTS

9.2.1.1 First Trimester

9.2.1.1.1 Blood Test

9.2.1.1.2 Nuchal Translucency Testing

9.2.1.2 Integrated Screening Test

9.2.1.2.1 First Trimester

9.2.1.2.2 Second Trimester

9.2.1.3 The Triple Screen or Quadraple Screen Test

9.2.1.4 Ultrasound

9.2.1.5 Cell Free DNA

9.2.2 DIAGNOSTIC TESTS

9.2.2.1 Chronic Villus Sampling

9.2.2.2 Amniocentesis

9.2.2.3 Precutaneous Umbical Cord Sampling

9.3 THERAPY

9.3.1 EARLY INTERVENTION THERAPY

9.3.1.1 Speech-Language Therapy

9.3.1.2 Physical Therapy

9.3.1.3 Occupational Therapy

9.3.1.4 Others

9.3.2 ASSISTIVE TECHNOLOGY

9.3.2.1 Hearing Aids

9.3.2.2 Glasses

9.3.2.3 Others

9.3.3 SURGERY

9.3.3.1 Atrioventricular Septal Defect (AVSD)

9.3.3.2 Duodenal Atresia

9.3.3.3 Others

9.3.4 OTHERS

10 EUROPE DOWN SYNDROME MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITAL

10.3 CLINICS

10.4 HOMECARE SETTING

10.5 OTHERS

11 EUROPE DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 RETAIL SALES

11.4 OTHERS

12 EUROPE DOWN SYNDROME MARKET, BY GEOGRAPHY

12.1 EUROPE

12.1.1 GERMANY

12.1.2 U.K.

12.1.3 FRANCE

12.1.4 ITALY

12.1.5 SPAIN

12.1.6 RUSSIA

12.1.7 POLAND

12.1.8 SWITZERLAND

12.1.9 NETHERLANDS

12.1.10 HUNGARY

12.1.11 AUSTRIA

12.1.12 NORWAY

12.1.13 IRELAND

12.1.14 TURKEY

12.1.15 LITHUANIA

12.1.16 REST OF EUROPE

13 EUROPE DOWN SYNDROME MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: EUROPE

14 COMPANY PROFILE

14.1 F. HOFFMANN-LA ROCHE LTD

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 PERKINELMER INC.

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 ILLUMINA, INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 THERMO FISHER SCIENTIFIC INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 MYRIAD GENETICS, INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 ABBOTT

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.7 ABNOVA CORPORATION

14.7.1 COMPANY SNAPSHOT

14.7.2 PRODUCT PORTFOLIO

14.7.3 RECENT DEVELOPMENTS

14.8 ASDCLINIC.CO.UK

14.8.1 COMPANY SNAPSHOT

14.8.2 SERVICE PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 ATILABIOSYSTEMS

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 BOSTON CHILDREN'S HOSPITAL

14.10.1 COMPANY SNAPSHOT

14.10.2 SERVICE PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 BOYS TOWN NATIONAL RESEARCH HOSPITAL

14.11.1 COMPANY SNAPSHOT

14.11.2 SERVICE PORTFOLIO

14.11.3 RECENT DEVELOPMENTS

14.12 CHILDREN'S HOSPITAL COLORADO

14.12.1 COMPANY SNAPSHOT

14.12.2 SERVICE PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 DEMEDITEC DIAGNOSTICS GMBH

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 DOWN SYNDROME CORK

14.14.1 COMPANY SNAPSHOT

14.14.2 SERVICE PORTFOLIO

14.14.3 RECENT DEVELOPMENTS

14.15 MAYO CLINIC HEALTH SYSTEM

14.15.1 COMPANY SNAPSHOT

14.15.2 SERVICE PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 NATERA, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 NEXT BIOSCIENCES

14.17.1 COMPANY SNAPSHOT

14.17.2 PRODUCT PORTFOLIO

14.17.3 RECENT DEVELOPMENTS

14.18 NOVUS BIOLOGICALS (A SUBSIDIARY OF BIO-TECHNE)

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENT

14.19 KID SENSE CHILD DEVELOPMENT CORPORATION PTY LTD

14.19.1 COMPANY SNAPSHOT

14.19.2 SERVICE PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 PHYSIO.CO.UK.

14.20.1 COMPANY SNAPSHOT

14.20.2 SERVICE PORTFOLIO

14.20.3 RECENT DEVELOPMENT

14.21 SYMBOL

14.21.1 COMPANY SNAPSHOT

14.21.2 SERVICE PORTFOLIO

14.21.3 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

LIST OF TABLES

TABLE 1 EUROPE DOWN SYNDROME MARKET: PIPELINE ANALYSIS

TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS

TABLE 3 EUROPE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 4 EUROPE TRISOMY 21 IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 EUROPE TRANSLOCATION DOWN SYNDROME IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 EUROPE MOSAIC DOWN SYNDROME IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 EUROPE DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 8 EUROPE DIAGNOSIS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 EUROPE DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 10 EUROPE DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 11 EUROPE FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 12 EUROPE INTEGRATED SCREENING TEST IN DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 13 EUROPE DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 14 EUROPE THERAPY IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 EUROPE THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 16 EUROPE EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 17 EUROPE ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 18 EUROPE SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 19 EUROPE THERAPY IN DOWN SYNDROM MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 20 EUROPE HOSPITAL IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 EUROPE CLINICS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 EUROPE HOMECARE SETTING IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 EUROPE THERAPY CENTERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 EUROPE OTHERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 EUROPE DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 26 EUROPE DIRECT TENDER IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 EUROPE RETAIL SALES IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 EUROPE OTHERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 EUROPE DOWN SYNDROME MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 30 EUROPE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 31 EUROPE DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 32 EUROPE DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 33 EUROPE SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 34 EUROPE FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 35 EUROPE INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 36 EUROPE DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 37 EUROPE THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 38 EUROPE EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 39 EUROPE ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 40 EUROPE SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 41 EUROPE DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 42 EUROPE DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 43 GERMANY DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 44 GERMANY DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 45 GERMANY DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 46 GERMANY SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 47 GERMANY FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 48 GERMANY INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 49 GERMANY DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 50 GERMANY THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 51 GERMANY EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 52 GERMANY ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 53 GERMANY SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 54 GERMANY DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 55 GERMANY DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 56 U.K. DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 57 U.K. DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 58 U.K. DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 59 U.K. SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 60 U.K. FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 61 U.K. INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 62 U.K. DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 63 U.K. THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 64 U.K. EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 65 U.K. ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 66 U.K. SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 67 U.K. DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 68 U.K. DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 69 FRANCE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 70 FRANCE DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 71 FRANCE DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 72 FRANCE SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 73 FRANCE FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 74 FRANCE INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 75 FRANCE DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 76 FRANCE THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 77 FRANCE EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 78 FRANCE ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 79 FRANCE SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 80 FRANCE DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 81 FRANCE DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 82 ITALY DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 83 ITALY DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 84 ITALY DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 85 ITALY SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 86 ITALY FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 87 ITALY INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 88 ITALY DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 89 ITALY THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 90 ITALY EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 91 ITALY ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 92 ITALY SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 93 ITALY DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 94 ITALY DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 SPAIN DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 96 SPAIN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 97 SPAIN DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 98 SPAIN SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 99 SPAIN FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 100 SPAIN INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 101 SPAIN DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 102 SPAIN THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 103 SPAIN EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 104 SPAIN ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 105 SPAIN SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 106 SPAIN DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 107 SPAIN DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 108 RUSSIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 109 RUSSIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 110 RUSSIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 111 RUSSIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 112 RUSSIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 113 RUSSIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 114 RUSSIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 115 RUSSIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 116 RUSSIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 117 RUSSIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 118 RUSSIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 119 RUSSIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 120 RUSSIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 121 POLAND DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 122 POLAND DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 123 POLAND DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 124 POLAND SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 125 POLAND FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 126 POLAND INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 127 POLAND DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 128 POLAND THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 129 POLAND EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 130 POLAND ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 131 POLAND SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 132 POLAND DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 133 POLAND DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 134 SWITZERLAND DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 135 SWITZERLAND DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 136 SWITZERLAND DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 137 SWITZERLAND SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 138 SWITZERLAND FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 139 SWITZERLAND INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 140 SWITZERLAND DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 141 SWITZERLAND THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 142 SWITZERLAND EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 143 SWITZERLAND ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 144 SWITZERLAND SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 145 SWITZERLAND DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 146 SWITZERLAND DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 147 NETHERLANDS DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 148 NETHERLANDS DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 149 NETHERLANDS DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 150 NETHERLANDS SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 151 NETHERLANDS FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 152 NETHERLANDS INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 153 NETHERLANDS DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 154 NETHERLANDS THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 155 NETHERLANDS EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 156 NETHERLANDS ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 157 NETHERLANDS SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 158 NETHERLANDS DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 159 NETHERLANDS DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 160 HUNGARY DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 161 HUNGARY DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 162 HUNGARY DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 163 HUNGARY SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 164 HUNGARY FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 165 HUNGARY INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 166 HUNGARY DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 167 HUNGARY THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 168 HUNGARY EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 169 HUNGARY ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 170 HUNGARY SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 171 HUNGARY DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 172 HUNGARY DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 173 AUSTRIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 174 AUSTRIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 175 AUSTRIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 176 AUSTRIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 177 AUSTRIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 178 AUSTRIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 179 AUSTRIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 180 AUSTRIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 181 AUSTRIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 182 AUSTRIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 183 AUSTRIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 184 AUSTRIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 185 AUSTRIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 186 NORWAY DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 187 NORWAY DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 188 NORWAY DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 189 NORWAY SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 190 NORWAY FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 191 NORWAY INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 192 NORWAY DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 193 NORWAY THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 194 NORWAY EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 195 NORWAY ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 196 NORWAY SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 197 NORWAY DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 198 NORWAY DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 199 IRELAND DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 200 IRELAND DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 201 IRELAND DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 202 IRELAND SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 203 IRELAND FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 204 IRELAND INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 205 IRELAND DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 206 IRELAND THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 207 IRELAND EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 208 IRELAND ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 209 IRELAND SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 210 IRELAND DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 211 IRELAND DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 212 TURKEY DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 213 TURKEY DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 214 TURKEY DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 215 TURKEY SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 216 TURKEY FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 217 TURKEY INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 218 TURKEY DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 219 TURKEY THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 220 TURKEY EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 221 TURKEY ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 222 TURKEY SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 223 TURKEY DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 224 TURKEY DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 225 LITHUANIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 226 LITHUANIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 227 LITHUANIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 228 LITHUANIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 229 LITHUANIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 230 LITHUANIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 231 LITHUANIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 232 LITHUANIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 233 LITHUANIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 234 LITHUANIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 235 LITHUANIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 236 LITHUANIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 237 LITHUANIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 238 REST OF EUROPE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

 

List of Figure

LIST OF FIGURES

FIGURE 1 EUROPE DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 2 EUROPE DOWN SYNDROME MARKET : DATA TRIANGULATION

FIGURE 3 EUROPE DOWN SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 EUROPE DOWN SYNDROME MARKET: EUROPE VS. REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE DOWN SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE DOWN SYNDROME MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE DOWN SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE DOWN SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE DOWN SYNDROME MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 EUROPE DOWN SYNDROME MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF DOWN SYNDROME AND OTHER RELATED DISORDERS AND RISING DEMAND FOR EFFECTIVE THERAPIES IS DRIVING THE EUROPE DOWN SYNDROME MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 TRISOMY 21 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DOWN SYNDROME MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE DOWN SYNDROME MARKET

FIGURE 15 EUROPE DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020

FIGURE 16 EUROPE DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 17 EUROPE DOWN SYNDROME MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 18 EUROPE DOWN SYNDROME MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 1 EUROPE DOWN SYNDROME MARKET: BY TREATMENT, 2020

FIGURE 2 EUROPE DOWN SYNDROME MARKET: BY TREATMENT, 2020-2028 (USD MILLION).

FIGURE 3 EUROPE DOWN SYNDROME MARKET: BY TREATMENT, CAGR (2020-2028)

FIGURE 4 EUROPE DOWN SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 5 EUROPE DOWN SYNDROME MARKET: BY END USER, 2020

FIGURE 6 EUROPE DOWN SYNDROME MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 7 EUROPE DOWN SYNDROME MARKET: BY END USER, CAGR (2020-2028)

FIGURE 8 EUROPE DOWN SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 9 EUROPE DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 10 EUROPE DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 11 EUROPE DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 12 EUROPE DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 13 EUROPE DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 14 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 15 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 16 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 17 EUROPE DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 18 EUROPE DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

 

View Infographics

LIST OF FIGURES

FIGURE 1 EUROPE DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 2 EUROPE DOWN SYNDROME MARKET : DATA TRIANGULATION

FIGURE 3 EUROPE DOWN SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 EUROPE DOWN SYNDROME MARKET: EUROPE VS. REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE DOWN SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE DOWN SYNDROME MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE DOWN SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE DOWN SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE DOWN SYNDROME MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 EUROPE DOWN SYNDROME MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF DOWN SYNDROME AND OTHER RELATED DISORDERS AND RISING DEMAND FOR EFFECTIVE THERAPIES IS DRIVING THE EUROPE DOWN SYNDROME MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 TRISOMY 21 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DOWN SYNDROME MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE DOWN SYNDROME MARKET

FIGURE 15 EUROPE DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020

FIGURE 16 EUROPE DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 17 EUROPE DOWN SYNDROME MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 18 EUROPE DOWN SYNDROME MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 1 EUROPE DOWN SYNDROME MARKET: BY TREATMENT, 2020

FIGURE 2 EUROPE DOWN SYNDROME MARKET: BY TREATMENT, 2020-2028 (USD MILLION).

FIGURE 3 EUROPE DOWN SYNDROME MARKET: BY TREATMENT, CAGR (2020-2028)

FIGURE 4 EUROPE DOWN SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 5 EUROPE DOWN SYNDROME MARKET: BY END USER, 2020

FIGURE 6 EUROPE DOWN SYNDROME MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 7 EUROPE DOWN SYNDROME MARKET: BY END USER, CAGR (2020-2028)

FIGURE 8 EUROPE DOWN SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 9 EUROPE DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 10 EUROPE DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 11 EUROPE DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 12 EUROPE DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 13 EUROPE DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 14 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 15 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 16 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 17 EUROPE DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 18 EUROPE DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19